(Q37077315)

18 August 2017

1 reference

title

Cardiometabolic features of polycystic ovary syndrome (English)

1 reference

polycystic ovary syndrome

18 August 2017

main subject

1 reference

1 reference

Leslie K Hoffman

1

1 reference

18 August 2017

David A Ehrmann

series ordinal

2

1 reference

18 August 2017

publication date

5 February 2008

1 reference

Nature Clinical Practice Endocrinology and Metabolism

18 August 2017

published in

1 reference

18 August 2017

volume

4

1 reference

18 August 2017

issue

4

1 reference

18 August 2017

page(s)

215-222

1 reference

Effects of weight loss on the hormonal profile in obese, infertile women

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

Influences of weight, body fat patterning and nutrition on the management of PCOS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

Testosterone administration to men increases hepatic lipase activity and decreases HDL and LDL size in 3 wk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

Prevalence of sleep-disordered breathing in women: effects of gender.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

Gender differences in the polysomnographic features of obstructive sleep apnea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Polycystic Ovary Syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Polycystic ovary syndrome: syndrome XX?

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Insulin resistance in the skeletal muscle of women with PCOS involves intrinsic and acquired defects in insulin signaling

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Enhanced mitogenic signaling in skeletal muscle of women with polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Sex hormone-binding globulin and female reproductive function.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Insulin-like growth factor I and insulin potentiate luteinizing hormone-induced androgen synthesis by rat ovarian thecal-interstitial cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Android subcutaneous adipose tissue topography in lean and obese women suffering from PCOS: comparison with type 2 diabetic women.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Relationship of androgenic activity to body fat topography, fat cell morphology, and metabolic aberrations in premenopausal women.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

The impact of obesity on hyperandrogenism and polycystic ovary syndrome in premenopausal women

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

The Relationship between C-Reactive Protein and Carotid Intima-Media Wall Thickness in Middle-Aged Women with Polycystic Ovary Syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Alterations in cardiac flow parameters in patients with polycystic ovarian syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Endothelial dysfunction in PCOS: role of obesity and adipose hormones.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Predictors of endothelial dysfunction in young women with polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Endothelial function varies according to insulin resistance disease type.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Cardiovascular risk in women with polycystic ovarian syndrome (PCOS)

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Metformin administration improves endothelial function in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Elevated ambulatory day-time blood pressure in women with polycystic ovary syndrome: a sign of a pre-hypertensive state?

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Ferriman Gallwey self-scoring I: performance assessment in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Obesity is the major determinant of the abnormalities in blood pressure found in young women with the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Relationship between androgen levels and blood pressure in young women with polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Sex hormone levels and risk of cardiovascular events in postmenopausal women

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Pathophysiology and types of dyslipidemia in PCOS.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Testosterone up-regulates scavenger receptor BI and stimulates cholesterol efflux from macrophages

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

The role of obesity in the increased prevalence of obstructive sleep apnea syndrome in patients with polycystic ovarian syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Prevalence of a positive family history of type 2 diabetes in women with polycystic ovarian disease.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Ethnicity and polycystic ovary syndrome are associated with independent and additive decreases in insulin action in Caribbean-Hispanic women.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Polycystic ovarian syndrome and insulin resistance in white and Mexican American women: a comparison of two distinct populations

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Evidence for metabolic and reproductive phenotypes in mothers of women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Metformin in polycystic ovary syndrome: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0755

7 January 2021

Identifiers

DOI

10.1038/NCPENDMET0755

1 reference

18 August 2017

1 reference